Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease

Patients will attend 4 scheduled visits: Screening Visit (Day -7 to Day 0), Visit 1/Baseline
Visit (Day 1), Visit 2 (Day 14) and Visit 3 (Day 28).

This study is sponsored by Alcon, A Novartis Company.

Inclusion Criteria:

- Must have TFBUT of ≤ 5 seconds in at least one eye at Screening visit.

- Must have best corrected visual acuity (BCVA) of ≥ 20/80 (or ≥ 55 letters score or ≥
0.6 early treatment diabetic retinopathy study (ETDRS) log of the minimum angle of
resolution (LogMAR) value) in both eyes at the Screening visit.

- Must be willing to discontinue use of all artificial tear supplements and use only the
study product as directed for the entire study duration.

Exclusion Criteria:

- History of hypersensitivity to the study drug or any of its excipients or to drugs of
similar chemical classes.

- Use of any topical ocular medication preserved with benzalkonium chloride or other
products known to be toxic to the tear film lipid layer within 1 month prior to the
Screening visit.

Other protocol-specified inclusion and exclusion criteria may apply.